StreetInsider.com News Articles

Form 8-K ARTELO BIOSCIENCES, INC. For: Oct 09

Fri, 09 Oct 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20261009/27172305.html

Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform

Wed, 07 Oct 2026 08:48:00 -0400

Presentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indications

BIO-Europe provides a key platform to advance ongoing discussions and expand partnering opportunities across Artelo’s growing portfolio

SOLANA BEACH, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with obesity, cancer, pain, dermatologic and neurological conditions, today announced that it has been selected to deliver a

Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform

Wed, 07 Oct 2026 08:48:00 -0400

Presentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indications

BIO-Europe provides a key platform to advance ongoing discussions and expand partnering opportunities across Artelo’s growing portfolio

Artelo files patent for ART27.13 in obesity, including GLP-1 combo

Wed, 23 Sep 2026 07:33:32 -0400

Artelo Biosciences (Nasdaq: ARTL) has filed a provisional patent application covering the use of its compound ART27.13 for the treatment of obesity, both as a standalone therapy and in combination with GLP-1 receptor agonists such as semaglutide, the active ingredient in Ozempic and Wegovy.

The filing follows nonclinical findings from Artelo's DIO-2 study conducted in obese mice over four weeks. ART27.13 as monotherapy produced approximately 20% weight loss from baseline, comparable to semaglutide alone. In combination with semaglutide, obese mice lost approximately 40% of baseline body weight. Approximately 80% of weight lost in ART27.13-treated groups was fat mass, compared with approximately

Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

Wed, 23 Sep 2026 07:33:00 -0400

As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks

Application expands Artelo’s intellectual property position for ART27.13 into obesity, where J.P. Morgan has projected the global GLP-1 market could reach $200 billion by 2030

New findings show the combination further improved oral glucose tolerance and increased bone mineral density, an effect not observed in any other treatment group

SOLANA BEACH, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”),

Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

Wed, 23 Sep 2026 07:33:00 -0400

As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks

Application expands Artelo’s intellectual property position for ART27.13 into obesity, where J.P. Morgan has projected the global GLP-1 market could reach $200 billion by 2030

New findings show the combination further improved oral glucose tolerance and increased bone mineral density, an effect not observed in any other treatment group

SOLANA BEACH, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”),

Artelo's ART27.13 matches semaglutide weight loss in mouse study

Wed, 16 Sep 2026 07:30:52 -0400

Artelo Biosciences (Nasdaq: ARTL) reported results from a nonclinical study showing its oral drug candidate ART27.13 produced weight loss comparable to semaglutide as a monotherapy, and approximately doubled weight loss when combined with semaglutide, in a diet-induced obesity mouse model.

In the study, obese mice treated with ART27.13 alone lost approximately 20% of their baseline body weight over four weeks, matching the weight loss observed with semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy. Mice treated with both ART27.13 and semaglutide lost approximately 40% of their baseline body weight, bringing them to the body weight of lean control animals.

The

Artelo's ART27.13 matches semaglutide weight loss in mouse study

Wed, 16 Sep 2026 07:30:52 -0400

The

Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity

Wed, 16 Sep 2026 07:30:00 -0400

Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic® and Wegovy®

Combining ART27.13 with semaglutide produced approximately 40% weight loss – double that of semaglutide alone

Results indicate that ART27.13 may possess the profile of a “metabolic regulator” capable of differentially modifying body weight and other parameters depending on the metabolic phenotype being treated

SOLANA BEACH, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a

Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity

Wed, 16 Sep 2026 07:30:00 -0400

Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic® and Wegovy®

Combining ART27.13 with semaglutide produced approximately 40% weight loss – double that of semaglutide alone

SOLANA BEACH, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a

Form 8-K ARTELO BIOSCIENCES, INC. For: Aug 26

Thu, 27 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260827/26985473.html

Form 8-K ARTELO BIOSCIENCES, INC. For: Aug 26

Thu, 27 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260827/26985473.html

Artelo Biosciences executes 1-for-9 reverse stock split

Thu, 27 Aug 2026 08:02:00 -0400

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company, announced a 1-for-9 reverse stock split of its common stock, with shares beginning to trade on a split-adjusted basis on the Nasdaq Capital Market at market open on Aug. 31, 2026.

As a result of the split, every nine shares of issued and outstanding common stock will be automatically combined into one share. The company stated the reverse split is intended to increase the per-share price of its common stock to improve marketability and liquidity.

No fractional shares will be issued. Stockholders who would otherwise be entitled to a fractional share will automatically

Artelo Biosciences executes 1-for-9 reverse stock split

Thu, 27 Aug 2026 08:02:00 -0400

No fractional shares will be issued. Stockholders who would otherwise be entitled to a fractional share will automatically

Artelo Biosciences Announces Reverse Stock Split

Thu, 27 Aug 2026 08:00:00 -0400

SOLANA BEACH, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced a 1-for-9 reverse stock split (“Reverse Split”) of the Company’s common stock (“Common Stock”). The Company’s Common Stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open on August 31, 2026. The Reverse Split is being effected in order to increase the price per share of the

Artelo Biosciences Announces Reverse Stock Split

Thu, 27 Aug 2026 08:00:00 -0400

Artelo Biosciences Announces Reverse Stock Split

Thu, 27 Aug 2026 08:00:00 -0400

Artelo Biosciences Announces Reverse Stock Split

Thu, 27 Aug 2026 08:00:00 -0400

Form 10-Q/A ARTELO BIOSCIENCES, INC. For: Jun 30

Thu, 20 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260820/26956571.html

Form 10-Q/A ARTELO BIOSCIENCES, INC. For: Jun 30

Thu, 20 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260820/26956571.html

Artelo Biosciences wins Japan patent allowance for ART27.13

Thu, 20 Aug 2026 08:52:14 -0400

Artelo Biosciences, Inc. (NASDAQ: ARTL) announced that the Japanese Patent Office has issued a notice of allowance with a Decision to Grant for the company's patent application covering the intended commercial formulation of ART27.13, a peripherally selective dual cannabinoid agonist.

The allowed claims in Japan protect compositions of ART27.13 dispersed in polyethylene glycol. The claims are consistent with those previously allowed in the United States and Europe, and all three jurisdictions are expected to provide patent protection through 2041.

ART27.13 was originally developed by AstraZeneca and fully licensed to Artelo in 2019. It is currently being evaluated in two Phase 2 clinical

Artelo Biosciences wins Japan patent allowance for ART27.13

Thu, 20 Aug 2026 08:52:14 -0400

ART27.13 was originally developed by AstraZeneca and fully licensed to Artelo in 2019. It is currently being evaluated in two Phase 2 clinical

Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13

Thu, 20 Aug 2026 08:52:00 -0400

SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allowance with a Decision to Grant for the Company’s patent application covering the intended commercial formulation of ART27.13, Artelo’s peripherally selective dual cannabinoid agonist currently being evaluated in two Phase 2 clinical trials.

The allowed claims in Japan protect compositions of ART27.13 dispersed in

Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13

Thu, 20 Aug 2026 08:52:00 -0400

The allowed claims in Japan protect compositions of ART27.13 dispersed in

Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13

Thu, 20 Aug 2026 08:52:00 -0400

The allowed claims in Japan protect compositions of ART27.13 dispersed in